wo papers published in Nature Medicine on Monday raised concerns that using CRISPR-Cas9 to edit genes could increase the chances that cancer cells develop. The stocks of CRISPR Therapeutics (NASDAQ:CRSP), Editas Medicine (NASDAQ:EDIT), and Intellia Therapeutics (NASDAQ:NTLA) plunged on the news.
Copyright © 2018,